Record mula sa primary source
Decision-gradePagbabago sa trial registry
RP-A501 · NCT06092034 registry update
primary_completion: 2028-04 → 2028-06; completion: 2032-04 → 2032-06; enrollment: 14 → 18; primary_outcomes: ['Evaluation of efficacy via primary endpoint comprised of LAMP2 myocardial tissue expression and left ventricular mass index'] → ['Evaluation of Efficacy: Improvement as assessed via primary endpoint comprised of LAMP2 myocardial tissue expression and left ventricular mass index (LVMI)']
Mahahalagang fact
- Na-file
- Okt 6, 2026, 03:21 PM
- Kaganapan
- Pagbabago sa trial registry
- Direksyon
- Neutral
- Kumpanya
RCKTRocket Pharmaceuticals- Asset
- RP-A501
- Pinagmulan
- ClinicalTrials.gov
- Kumpiyansa
- May source
- pivotal N
- 12
- phase1 lvm
- 5/6 below baseline at 3-7y
- lvm reduction
- ≥10%
- lamp2 expression
- ≥Grade 1
- original dose lvm
- 3/4 achieved ≥10% reduction
- success threshold
- at least 7/12 patients meeting both co-primary endpoints
Higit pa tungkol sa asset na ito
Okt 6, 2026
09:15 PM
RCKTRocket PharmaceuticalsSet 15, 2026
11:06 AM
RCKTRocket Pharmaceuticals